Development of resistance-breaking cancer therapies
TOLREMO therapeutics AG
Incorporated
16.03.2017Headquarters
BaselSupport
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments.
News
Regulatory milestones and clinical progress for Swiss biotechs (startupticker.ch)
Schweizer Biotech-Startups dominieren europäischen Award (startupticker.ch)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
Innosuisse funded 45 Start-up innovation projects (startupticker.ch)
New additions to startups’ board of directors (startupticker.ch)
TOLREMO doses first patient in Phase 1 clinical trial (startupticker.ch)
SEF.WomenAward reveals the finalists (startupticker.ch)
TOLREMO therapeutics Completes USD 39 Million Series A Financing Round (startupticker.ch)
TOLREMO Therapeutics secures USD 39 Million in Series A funding to fight non-genetic cancer drug resistance (venturelab.swiss)
The 18 most promising biotech startups, according to investors (TOP 100)
Tolremo’s founder Stefanie Flückiger-Mangual is the Innovator of the Year (startupticker.ch)
TOP 100 Satellite Event: 5 TOP 100 Swiss Startups pitch to Credit Suisse investors in Basel (TOP 100)
Female Innovation Forum: six startups nominated for two awards (startupticker.ch)
Das sind die Finalisten des Swiss Technology Award 2020 (startupticker.ch)
Three Swiss projects contest for the EIT Awards 2020 (startupticker.ch)
Female entrepreneurs in the spotlight (startupticker.ch)
Additional capital for TOLREMO therapeutics (startupticker.ch)
TOLREMO receives additional CHF 4.7M in Series A financing (venturelab.swiss)
BaseLaunch accelerator nominates 4 startups for phase 2 (startupticker.ch)
10 Swiss Biotech Startups to Watch in 2020 (venturelab.swiss)
Milestones news
>>Venture>> finalist: TOLREMO has one of Switzerland's most promising startup business plans
Bilan names TOLREMO one of its 'TOP50 Swiss startups in which to invest 2019'
Videos and Presentations
Swiss Innovation Challenge 2019 (Wirtschaftskammer Baselland)
SCSN 2019
Interview with Stefanie Flückiger-Mangual